Kainova Therapeutics

Kainova Therapeutics develops small molecules targeting G-coupled protein receptors.

ActiveBioTechHealth CarePharmaceuticalTherapeutics

Updated: Feb 17, 2026 ·

About

Kainova Therapeutics is a clinical-stage biopharmaceutical company that develops small molecules targeting G-coupled protein receptors (GPCRs). Formerly known as Domain Therapeutics, the company transitioned to its new identity to align with its scientific ambitions and clinical focus. It is dedicated to advancing a pipeline of GPCR-modulating therapies, particularly within the field of immuno-oncology.

The company's work involves the discovery and early development of these small molecules, aiming to address various therapeutic areas. Kainova Therapeutics operates as a private entity, with its headquarters located in Illkirch, Alsace, France.

Recent News & Mentions

Feb 9, 2026FundingKainova Therapeutics - Series B

Financial History

Kainova Therapeutics has raised $23.5M across 1 funding round. Most recently, it raised $23.5M Series B in February 2026.

Total Raised

$23.5M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 9, 2026	$23.5M Series B	Investissement Quebec	3B Future Health Fund, adMare Bio Innovations, CTI Life Sciences Fund, Panacea Venture, Schroders Capital, Seido Capital, Seventure Partners, Turenne Capital, Viva BioInnovator

Financial History

Kainova Therapeutics has raised $23.5M across 1 funding round.

Total Raised

$23.5M

Valuation

N/A

Deep Dive

Kainova Therapeutics, previously known as Domain Therapeutics, is a biopharmaceutical company specializing in the discovery and development of small molecules that modulate G-coupled protein receptors (GPCRs). The company officially adopted the name Kainova Therapeutics on January 12, 2026, marking a new chapter in its strategic direction and clinical objectives, particularly within immuno-oncology.

The company's core scientific approach centers on leveraging GPCR targets for therapeutic intervention. GPCRs are a large family of cell surface receptors that play critical roles in various physiological processes, making them attractive targets for drug development. Kainova Therapeutics aims to develop novel therapies by precisely modulating the activity of these receptors.

As a clinical-stage entity, Kainova Therapeutics is actively advancing a pipeline of drug candidates. Its focus on immuno-oncology highlights an effort to develop treatments that can harness the body's immune system to fight cancer, utilizing its expertise in GPCR modulation to achieve this goal.

The company is headquartered in Illkirch, Alsace, France, and operates as a privately held organization. Its development efforts are supported by a diverse group of investors, with 26 entities contributing to its funding. Notable recent investors include adMare BioInnovations and Viva BioInnovator, indicating continued financial backing for its research and development initiatives.

Sources

Frequently Asked Questions

What was the context for Kainova Therapeutics' name change from Domain Therapeutics?

Kainova Therapeutics, formerly Domain Therapeutics, changed its name on January 12, 2026, to better align with its evolving scientific ambitions and clinical focus, particularly in the field of immuno-oncology.

Who are some of the key investors supporting Kainova Therapeutics?

Kainova Therapeutics is funded by 26 investors, with adMare BioInnovations and Viva BioInnovator identified as some of the most recent investors supporting the company's initiatives.

Frequently Asked Questions

What was the context for Kainova Therapeutics' name change from Domain Therapeutics?

Who are some of the key investors supporting Kainova Therapeutics?

Kainova Therapeutics is funded by 26 investors, with adMare BioInnovations and Viva BioInnovator identified as some of the most recent investors supporting the company's initiatives.